About: Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
Creator	Wang, Dong Ye, Mingxiang Zhang, Fang Fu, Dian Lv, Tangfeng Ren, Yi Xia, Xinyi Wang, Faxiang
Source	Medline; PMC
abstract	The discovery of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and the outbreak of coronavirus disease 2019 (COVID‐19) are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID‐19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID‐19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID‐19 patients were enrolled and received the transfusion of ABO‐compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS‐CoV‐2 in throat swab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti‐SARS‐CoV‐2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID‐19. This intervention has a special significance for eliminating SARS‐CoV‐2 and is believed to be a promising state‐of‐art therapy during COVID‐19 pandemic crisis. This article is protected by copyright. All rights reserved.
has issue date	2020-04-15(xsd:dateTime)
bibo:doi	10.1002/jmv.25882
bibo:pmid	32293713
has license	no-cc
sha1sum (hex)	879415152d253eb38de4999ae7efd745230c15d8
schema:url	https://doi.org/10.1002/jmv.25882
resource representing a document's title	Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
has PubMed Central identifier	PMC7262027
has PubMed identifier	32293713
schema:publication	J Med Virol
resource representing a document's body	covid:879415152d253eb38de4999ae7efd745230c15d8#body_text
is schema:about of	named entity 'evaluate' named entity 'public health emergency' named entity 'confirmed' named entity 'discovery' named entity 'S protein' named entity 'antigen-antibody complex' named entity 'convalescent plasma' named entity 'Wuhan' named entity 'Shanghai' named entity 'COVID-19' named entity 'bronchial' named entity 'Wuhan' named entity 'plasma' named entity 'Accepted' named entity 'China' named entity 'Wuhan' named entity 'lungs' named entity 'COVID' named entity 'nucleic acid' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'nucleic acid' named entity 'symptom' named entity 'single-stranded RNA' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'COVID' named entity 'C-reactive protein' named entity 'Reverse transcription' named entity 'shortness of breath' named entity 'IgM' named entity 'antibodies' named entity 'chest CT' named entity 'lung' named entity 'COVID' named entity 'convalescent plasma' named entity 'throat swab' named entity 'SARS-CoV-2' named entity 'endogenous' named entity 'zoonotic' named entity 'IgG' named entity 'infection' named entity 'human coronavirus' named entity 'Chest CT' named entity 'convalescent plasma therapy' named entity 'myalgia' named entity 'fever' named entity 'throat swab' named entity 'SARS-CoV-2' named entity 'Bronchoalveolar lavage fluid' named entity 'protein' named entity 'COVID' named entity 'SARS' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'March 13' named entity 'lymphopenia' named entity 'chest CT' named entity 'shortness of breath' named entity 'cough' named entity 'influenza' named entity 'March 5' named entity 'coronavirus' named entity 'myalgia' named entity 'convalescent plasma therapy' named entity 'transfusion' named entity 'human-to-human' named entity 'March 14' named entity 'coronavirus disease 2019' named entity 'Laboratory test' named entity 'real-time PCR' named entity 'January 29' named entity 'chemiluminescence' named entity 'primers' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software